The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
[EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
申请人:GENZYME CORP
公开号:WO2015089067A1
公开(公告)日:2015-06-18
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.
Ester bio-isosteres: synthesis of oxadiazolyl-1-azabicyclo[2.2.1]heptanes as muscarinic agonists
作者:John Saunders、Angus M. MacLeod、Kevin Merchant、Graham A. Showell、Roger J. Snow、Leslie J. Street、Raymond Baker
DOI:10.1039/c39880001618
日期:——
The methyl ester functionality in arecoline and related esters has been replaced by 1,2,4-oxadiazole to generate the most potent and efficacious muscarinicagonists known.
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.